Value for Money of CAR-T Cell Therapy for Patients with Diffuse Large B-cell Lymphoma in China: Evidence from a Cost-Effectiveness Analysis.
Weijia WuYuping ZhouYannan WangSyed Afroz KeramatNamal N BalasooriyaZixuan ZhaoYi YangTracy ComansHengjin DongPublished in: Applied health economics and health policy (2023)
Our results demonstrated that CAR-T treatments are not cost effective in any-line settings for DLBCL patients at the WHO-recommended willingness-to-pay threshold (CNY257,241 per QALY) in the base-case analysis. Price reduction of CAR-T therapies is the main approach for lowering ICERs and ensuring that the drug costs are proportional to patient health benefits.